BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26968754)

  • 1. Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
    Flatmark K; Saelen MG; Hole KH; Abrahamsen TW; Fleten KG; Hektoen HH; Redalen KR; Seierstad T; Dueland S; Ree AH
    Radiother Oncol; 2016 Jun; 119(3):505-11. PubMed ID: 26968754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
    Voogt ELK; Schaap DP; van den Berg K; Nieuwenhuijzen GAP; Bloemen JG; Creemers GJ; Willems J; Cnossen JS; Peulen HMU; Nederend J; van Lijnschoten G; Burger JWA; Rutten HJT
    Eur J Surg Oncol; 2021 Sep; 47(9):2429-2435. PubMed ID: 34030921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.
    Seierstad T; Hole KH; Grøholt KK; Dueland S; Ree AH; Flatmark K; Redalen KR
    Br J Radiol; 2015 Jul; 88(1051):20150097. PubMed ID: 25899892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.
    Dueland S; Ree AH; Grøholt KK; Saelen MG; Folkvord S; Hole KH; Seierstad T; Larsen SG; Giercksky KE; Wiig JN; Boye K; Flatmark K
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):532-9. PubMed ID: 26888115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
    Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
    J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.
    Maréchal R; Vos B; Polus M; Delaunoit T; Peeters M; Demetter P; Hendlisz A; Demols A; Franchimont D; Verset G; Van Houtte P; Van de Stadt J; Van Laethem JL
    Ann Oncol; 2012 Jun; 23(6):1525-30. PubMed ID: 22039087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer.
    Beppu N; Yoshie H; Kimura F; Aihara T; Doi H; Kamikonya N; Matsubara N; Tomita N; Yanagi H; Yamanaka N
    Surg Today; 2016 Oct; 46(10):1123-31. PubMed ID: 26704191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
    Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
    Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
    Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
    Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis.
    Yang YJ; Cao L; Li ZW; Zhao L; Wu HF; Yue D; Yang JL; Zhou ZR; Liu SX
    Oncotarget; 2016 Jul; 7(29):45513-45524. PubMed ID: 27322422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
    Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
    Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
    Larsen FO; Markussen A; Jensen BV; Fromm AL; Vistisen KK; Parner VK; Linnemann D; Hansen RH; Johannesen HH; Schou JV
    Clin Colorectal Cancer; 2017 Jun; 16(2):e7-e14. PubMed ID: 27743742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.
    Ng SY; Colborn KL; Cambridge L; Cercek A; Reidy-Lagunes DL; Segal N; Stadler Z; Saltz LB; Paty PB; Guillem J; Weiser MR; Nash G; Garcia-Aguilar J; Goodman KA
    Clin Colorectal Cancer; 2019 Sep; 18(3):167-174. PubMed ID: 31104990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.
    Meltzer S; Kalanxhi E; Hektoen HH; Dueland S; Flatmark K; Redalen KR; Ree AH
    Oncotarget; 2016 Jun; 7(23):34907-17. PubMed ID: 27145458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
    Gérard JP; Chapet O; Nemoz C; Romestaing P; Mornex F; Coquard R; Barbet N; Atlan D; Adeleine P; Freyer G
    J Clin Oncol; 2003 Mar; 21(6):1119-24. PubMed ID: 12637479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.